COO Cooper Companies Inc.

CooperCompanies Appoints Holly Sheffield as President, CooperSurgical and Announces Robert Auerbach, M.D. to Retire

CooperCompanies Appoints Holly Sheffield as President, CooperSurgical and Announces Robert Auerbach, M.D. to Retire

SAN RAMON, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE:COO) today announced that Holly Sheffield has been appointed President of CooperSurgical effective July 13, 2020, reporting to Albert White, President and CEO. Ms. Sheffield will succeed Robert Auerbach, M.D. who is retiring.  As part of this planned transition Dr. Auerbach will act in an advisory capacity until February 1, 2021.

“On behalf of everyone at Cooper, I want to thank Bob for his leadership and significant contributions to our company,” said Al White, President and CEO. “Bob has been an important member of the Cooper team for more than 15 years and has played a key role in helping CooperSurgical grow to where it is today.  We look forward to a seamless transition of responsibilities and wish him all the best in his retirement.”

White added, “Holly is a very strong leader and I’m highly confident she has the capabilities required to continue driving CooperSurgical’s global success.”

Ms. Sheffield joined Cooper as Executive Vice President and Chief Strategy Officer of CooperCompanies in June 2018. She joined Cooper from UBS Securities LLC, where she was Managing Director, Global Head of Medical Technology for the Healthcare Banking group. She holds an MBA from Columbia Business School and a BS from Cornell University.

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit .

Contact:

Kim Duncan

Vice President, Investor Relations and Risk Management

925-460-3663

EN
06/07/2020

Underlying

COOCooper Companies Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cooper Companies Inc.

Free Trial
COO Cooper Companie...

Cooper Companies Inc: 3 directors

A director at Cooper Companies Inc bought 2,000 shares at 82.500USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

COO COOPER COMPANIES INC.
12/17/25 December 17, 2025 1 EN
 PRESS RELEASE
Free
COO Cooper Companie...

CooperCompanies Announces New Chair of the Board and Strategic Review

CooperCompanies Announces New Chair of the Board and Strategic Review SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that its Board of Directors has appointed Colleen Jay to succeed current Chair Robert Weiss, effective January 2, 2026. Mr. Weiss will remain on the Board and stand for reelection for the upcoming year, marking his final term. The Company also announced a formal strategic review aimed at identifying opportunities to enhance long-term shareholder value. “Bob’s vision, industry knowledge, ...

December 4, 2025 1 EN
 PRESS RELEASE
Free
COO Cooper Companie...

CooperCompanies Announces Fourth Quarter and Full Year 2025 Results

CooperCompanies Announces Fourth Quarter and Full Year 2025 Results SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today financial results for its fiscal fourth quarter and full year ended October 31, 2025. Fourth quarter 2025 revenue of $1,065.2 million, up 5%, or up 3% organically. Fiscal year 2025 revenue of $4.1 billion, up 5%, or up 4% organically.Fourth quarter 2025 GAAP diluted earnings per share (EPS) of $0.43, down 27%. Fiscal 2025 GAAP diluted EPS of $1.87, down 4%.Fourth quarter 2025 non-GA...

December 4, 2025 1 EN
 PRESS RELEASE
Free
COO Cooper Companie...

CooperCompanies Announces Release Date for Fourth Quarter and Full Yea...

CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025 SAN RAMON, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report fourth quarter and full year 2025 financial results on Thursday, December 4, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 2700541. A simultaneous audio webcast and subsequent replay c...

November 4, 2025 1 EN
 PRESS RELEASE
Free
COO Cooper Companie...

CooperCompanies Announces Expanded Share Repurchase Program

CooperCompanies Announces Expanded Share Repurchase Program SAN RAMON, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today its Board of Directors has approved a $1 billion increase in the Company’s share repurchase program. The share repurchase program now totals $2 billion. “We are pleased to announce that our Board of Directors has authorized an increase to our share repurchase program,” said Al White, President and Chief Executive Officer. “This decision underscores the strength of our balance sheet and cas...

September 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch